Guardant Health – Radius Health Partner for Breast Cancer Therapy

Returning guest, Daniel Simon, SVP, BioPharma Business Development at Guardant Health, a leading precision oncology company discusses a strategic collaboration with Radius Health for the commercialization and use of the Guardant360® CDx  liquid biopsy companion diagnostic for elacestrant (RAD1901), an investigational therapy being studied for the treatment of advanced breast cancer in combination with hormone therapy.

Daniel Simon is responsible for building Guardant’s partnerships with pharmaceutical and biotechnology companies using the Digital Sequencing technology platform. Daniel brings more than a decade of experience in the life sciences industry across business development, strategy, and operations. Previously, Daniel served in roles at MyoKardia, Onyx Pharmaceuticals, McKinsey & Company, and Genentech. He holds an MBA from the University of Pennsylvania’s Wharton School and an MA Hons. in Natural Sciences from the University of Cambridge.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.